In Brief: Beconase Rx-to-OTC switch
Executive Summary
Beconase Rx-to-OTC switch: FDA's Nonprescription Drugs and Pulmonary & Allergy Drugs Advisory committees will review Glaxo Wellcome's switch NDA (20-840) for beclomethasone dipropionate nasal spray .042% on Sept. 19 for OTC treatment and prevention of seasonal allergic rhinitis symptoms in patients over the age of 12. The meeting will begin at 8:30 a.m. at the Gaithersburg, Md. Holiday Inn...